NCT05352035 is a clinical trial in Non-small Cell Lung Cancer, sponsored by Peking University People's Hospital.

Who is sponsoring NCT05352035?

NCT05352035 is sponsored by Peking University People's Hospital.

What condition does NCT05352035 study?

NCT05352035 studies Non-small Cell Lung Cancer.

Is NCT05352035 still recruiting?

NCT05352035 is currently recruiting now. Last updated 30 April 2025.

Last reviewed 2025-04-30 · How we verify

NCT05352035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiomics Tumor Evolution Model of NSCLC

Recruiting now Last updated 30 April 2025

What this trial tests

trial in Non-small Cell Lung Cancer in 300 participants. Currently enrolling.

Timeline

20 April 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	20 April 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across China

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Peking University People's Hospital

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance.
Sabit H, Arneth B, Pawlik TM, Abdel-Ghany S, et al · · 2025 · cited 23× · PMID 39861138 · DOI 10.3390/ph18010075
Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study.
Wang W, He Y, Yuan X, Weng L, et al · · 2025 · PMID 41438463 · DOI 10.1515/jtim-2025-0047

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05352035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 30 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05352035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing